Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer - Seite 3
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences
and outcomes, the impact of data on clinicians' decision-making, and Accuray's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks
and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including
new product offerings, the company's ability to develop new products or enhance existing products to meet customers' needs, delays in the development or release of new offerings and such other
risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 24,
2018, the company's quarterly report on Form 10-Q, filed with the SEC on February 8, 2019, and as updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contacts: |
|
Beth Kaplan |
Jayme Maniatis |
Public Relations Director, Accuray |
MSLGROUP |
+1 (408) 789-4426 |
+1 (781) 684-6610 |
bkaplan@accuray.com |
accuray@mslgroup.com |
Lesen Sie auch